Atlas Trials

Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer

Clinical trial NCT04758780 · COMPLETED

Trial details

NCT number
NCT04758780
Sponsor
Institut Cancerologie de l'Ouest
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2021-09-21
Primary completion
2023-03-31
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.